Clinical trial · no report yet · Phase 3
GLORIOSA
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05445778 ↗
- Active not recruiting
- AbbVie
- 74 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 41 | |
| Podcasts | 33 |
The trial
ClinicalTrials.gov- Official title
- Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
- Interventions
- Mirvetuximab soravtansine plus Bevacizumab; Bevacizumab
- Arms
- Arm 1 · Experimental
- Arm 2 · Active comparator
- Enrollment
- 520
- Primary outcomes
- Assess Progression-free survival (PFS)
- Sponsor
- AbbVie with GOG Foundation
- Start
- Mar 15, 2023
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05445778 · updated Jun 2, 2026
Publications
linked from the registry- O'Malley DM, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRalpha-high platinum-sensitive ovarian cancer. Future Oncol. 2024;20(32):2423-2436. doi: 10.1080/14796694.2024.2372241. Epub 2024 Jul 31. PubMed 39082675